Updated from 1:13 p.m. EDTEli Lilly's ( LLY) profit beat and GlaxoSmithKline's ( GSK) move to buy Stiefel Laboratories weren't enough to lift widely held health care stocks above the slumping broader market on Monday. Eli Lilly reported a 23% rise in first-quarter profit driven by flat costs and healthy sales, but it saw flat or decreased sales for two of its top-selling drugs. Zyprexa had flat sales of $1.12 billion, and cancer drug Gemzar saw a 14% drop in sales to $367.8 million, according to The Associated Press. Lilly backed full-year profit guidance of between $4 and $4.25, in line with analysts' estimate of $4.14 per share. Eli Lilly's stock suffered Monday, recently falling 1.5% to $33.25. Meanwhile, GlaxoSmithKline shares were falling after the U.K. health powerhouse announced it would buy privately held dermatological products maker Stiefel Laboratories for $2.9 billion in cash. The deal is expected to be dilutive to shares in 2009, and 1% to 2% accretive next year. Stiefel, which is partly owned by Blackstone Group ( BX), reportedly had drawn interest from Johnson & Johnson and Novartis ( NVS) earlier in the year. Glaxo shares were recently falling 1.7% to $30.09. Elsewhere: Johnson & Johnson ( JNJ) shares were down 0.9% to $52.57. Pfizer ( PFE) shares were down 3.7% to $13.64. Bristol-Myers Squibb ( BMY) was falling 2.1% to $20.23. Merck ( MRK) shares were down 1.4% to $25.37. Procter & Gamble ( PG), which on Monday received an upgrade to Buy from Neutral at Sun Trust Robinson Humphrey, was falling 1% to $51.17. Novo Nordisk ( NVO) bucked the trend, with shares recently rising 0.5% to $44.43.